Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stock has a great upside potential
I'm bullish and will always be
You have the right to be negative
$PSYC game on tomorrow
Investor interest in alternative psychedelic medicine is on the rise, with several high-profile investors and celebrities endorsing the psychedelic medicine market, either by joining strategic advisory boards or making sizable investments. In fact, there is so much interest in psychedelics medicine that some analysts see the industry bringing in $5 billion annually.
Should run this week
Yes psychedelic rush coming
Get ready for a run here
Even former Chief Scientific Officer of Neuroscience of Pfizer (NYSE:PFE) Michael Ehlers has joined the psychedelic research movement by joining the advisory board of a psychedelic clinics company Field Trip.
"Therapeutic psychedelics are some of the most exciting new approaches being investigated to fight the burgeoning global mental health crisis happening right now," Ehlers said. "It is critical that we make smart investments, develop the research rigorously, and advance this industry in a thoughtful way."
Johnson & Johnson arguably kickstarted psychedelic medicines' move into mainstream medicine when its Ketamine-like drug treatment for severe depression was handed FDA approval
In recent years, there has been a renewed interest in the use of psychedelics in psychiatric research and practices.
After decades of having a bad rep, psychedelics are making their way back into the medical world and are being touted for their ability to treat various mental illnesses.
Today, with a net worth of roughly $400 million accrued through various enterprises, Angermayer is one of the driving forces behind the movement to turn long-shunned psychoactive substances, like the psilocybin derived from so-called magic mushrooms, into approved medications for depression and other mental illnesses. Though he still resolutely won’t touch even a drop of alcohol, he has banded together a team of like-minded entrepreneurs — including Silicon Valley billionaire Peter Thiel — to invest in a handful of startups focused on developing psychedelics.
Research on psychedelics, which have been profoundly stigmatized, highly restricted, and tragically undeveloped for more than half a century, is stirring back to life and rekindling scientific, medical, and cultural interest in these compounds.
AVERAGE VOL (30D) 2,243,953
52WK RANGE 0.0049 - 0.41
Wrong board sorry
Held at DTC 97,798,512 08/04/2020
Unrestricted 113,644,529 08/04/2020
Restricted 61,418,175 08/04/2020
Outstanding Shares 175,062,704
08/04/2020
Authorized Shares 400,000,000
08/04/2020
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential. Since 2017, PSYC has been a pioneer in the emerging software and payment processing sector of the cannabis industry and has established itself as a trusted resource for businesses operating within the industry. Most recently, PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA's more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. Our forward-thinking approach and passion for new and emerging industries are part of what makes us the right TRAC to follow. Our psychedelic-focused website can be viewed at: www.psychedelicspotlight.com
Just need more juice
Always run on volume anyway so we are technically good to go
As long as we can swing it we good
Looking better end of day
Top OTC to watch: $CBDD $RXMD $PSRU $ALST
$RXMD Progressive Care Reports June 2020 Performance Data: Preliminary Q2 Sales Up 33% to $9.32M https://www.otcmarkets.com/stock/RXMD/news/Progressive-Care-Reports-June-2020-Performance-Data-Preliminary-Q2-Sales-Up-33-to-932M?id=268672 $IBB $GILD $NVS $PFE $MRK $AMGN $BSX
$RXMD Progressive Care Reports June 2020 Performance Data: Preliminary Q2 Sales Up 33% to $9.32M https://www.otcmarkets.com/stock/RXMD/news/Progressive-Care-Reports-June-2020-Performance-Data-Preliminary-Q2-Sales-Up-33-to-932M?id=268672 $IBB $GILD $NVS $PFE $MRK $AMGN $BSX
$PSRU 0.048 ask now expecting a run soon, thin all the way up to a dime!
$PSRU 0.048 ask now expecting a run soon, thin all the way up to a dime!
$CBDD low priced cannabis stock on watch!
0.63 x 0.64 now
$RXMD 0.069 ask now!!!! looks like new high coming shortly!
new high coming soon
$LEAS Set to Take Fintech, IoT Markets by Storm?
https://dailytrendingstocks.com/leas-set-to-take-fintech-iot-markets-by-storm/
$LEAS Set to Take Fintech, IoT Markets by Storm?
https://dailytrendingstocks.com/leas-set-to-take-fintech-iot-markets-by-storm/
$RXMD 0.0675 ask!